Special Issue "Atopic Dermatitis: Research and Clinical Updates and Perspectives"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 20 July 2022 | Viewed by 1111

Special Issue Editor

Prof. Dr. Stamatis Gregoriou
E-Mail Website
Guest Editor
1st Department of Dermatology and Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, 10679 Athens, Greece
Interests: clinical dermatology; skin; psoriasis; dermatology; pediatric dermatology; trichology; nails; acne; atopic dermatitis; skin diseases; rosacea; alopecia areata

Special Issue Information

Dear Colleagues,

Atopic dermatitis (AD), or atopic eczema, is a chronic inflammatory cutaneous disorder. Novel insights in its pathophysiology and breakthrough therapeutics have changed the landscape of AD in the last decade. Genetic polymorphisms, microbiome diversity, skin barrier defects, modulation of innate and adaptive immunity, environmental exposure, and better understanding of the immunologic inflammatory pathways of both eczema and pruritus have shed new light on AD patients phenotypes and endotypes. In addition, several new treatment options, both topical and systemic, including biologics and small molecules, which target selective mediators in the inflammatory pathway have been added to the classical therapies. The aim of this issue is to present the forefront of recent research that has improved our understanding of AD and the new treatment options that are already available or are expected to be available in the near future.

Prof. Dr. Stamatis Gregoriou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Atopic dermatitis Biomarkers
  • Exposome
  • interleukin 4/13
  • pruritus
  • Th2 response
  • treatment
  • biologics
  • small molecules
  • JAK

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

Editorial
Atopic Dermatitis: Sailing beyond the Sunset with a Multitude of Novel Treatments
J. Clin. Med. 2022, 11(12), 3475; https://doi.org/10.3390/jcm11123475 - 16 Jun 2022
Viewed by 341
Abstract
Atopic eczema or dermatitis (AD) is a chronic pruritic inflammatory cutaneous disorder with an incidence up to 20% in children and 10% in adults depending on region and ethnicity [...] Full article
(This article belongs to the Special Issue Atopic Dermatitis: Research and Clinical Updates and Perspectives)

Research

Jump to: Editorial

Article
Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study
J. Clin. Med. 2022, 11(12), 3341; https://doi.org/10.3390/jcm11123341 - 10 Jun 2022
Viewed by 335
Abstract
Epidermal barrier dysfunction plays an important role in atopic dermatitis (AD). The difficulty of objectively assessing AD severity and the introduction of new biologicals into clinical practice highlight the need to find parameters to monitor clinical outcomes. The aim of this study is [...] Read more.
Epidermal barrier dysfunction plays an important role in atopic dermatitis (AD). The difficulty of objectively assessing AD severity and the introduction of new biologicals into clinical practice highlight the need to find parameters to monitor clinical outcomes. The aim of this study is to evaluate the impact of dupilumab on skin barrier function and compare it with other treatments in patients with AD. A prospective observational study was conducted in adults with AD treated with topical corticosteroids (TCS), cyclosporine, or dupilumab. The main outcome measures after 16 weeks of treatment were Eczema Area and Severity (EASI)-50 (50% improvement in EASI), and transepidermal water loss (TEWL)-50 (50% improvement in TEWL). Forty-six patients with AD were included in the study. The proportion of patients who achieved EASI-50 at week 16 was significantly higher in patients receiving dupilumab (81.8% vs. 28.6% vs. 40%, p = 0.004). In eczematous lesions, TEWL decreased in patients receiving dupilumab (31.02 vs. 12.10 g·h−1·m−2, p < 0.001) and TCS (25.30 vs. 14.88 g·h−1·m−2, p = 0.047). The proportion of patients who achieved TEWL-50 at week 16 was higher for dupilumab than for cyclosporine or TCS. Temperature only decreased in the dupilumab group. Stratum corneum hydration increased in eczematous lesions and non-involved skin only in patients with dupilumab. In conclusion, dupilumab improves skin barrier function in patients with AD better than TCS or cyclosporine, both in eczematous lesions and in non-lesioned skin. Full article
(This article belongs to the Special Issue Atopic Dermatitis: Research and Clinical Updates and Perspectives)
Show Figures

Figure 1

Back to TopTop